Marina Cerrone

Research Assistant Professor of Medicine

NYU School of Medicine
Country flagUnited States
ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (4)

Background Desmoplakin (DSP) cardiomyopathy, caused by variants in the gene DSP , is a unique subtype of cardiomyopathy distinct from typical dilated or arrhythmogenic right ventricular cardiomyopathies. Specific diagnostic and disease staging criteria have yet to be developed for DSP cardiomyopathy. Objective Utilizing a large cohort of DSP cardiomyopathy patients and their genotype-positive family members, this study aims to develop diagnostic and disease staging criteria for DSP cardiomyopathy. Methods Patients from the DSP -ERADOS Network with complete rhythm monitoring, electrocardiogram and cardiac magnetic resonance imaging were enrolled. Diagnostic criteria were assessed in initially-presenting patients (probands) and their genotype-positive family members. Early disease criteria (with preserved left ventricular ejection fraction, LVEF) were integrated into standard LVEF-based classifications. Diagnostic and staging criteria were assessed by time-event analyses (major ventricular arrhythmia and heart failure events). Results A total of 605 patients with complete diagnostic testing were included (mean age 40 yr, 60% female, 40% probands). The most prevalent disease features in probands were premature ventricular contractions (PVCs) >500/24hr (66%), nonsustained ventricular tachycardia (NSVT, 29%), LV late gadolinium enhancement (LGE, 53%), and reduced LVEF (44%). The presence of any one of these features was 97% sensitive for diagnosis (along with a DSP pathogenic variant) and were therefore considered as diagnostic criteria. Using these criteria, 77% of genotype-positive family members were considered clinically affected. Isolated right ventricular (RV) involvement occurred in only 0.7%. The absence of diagnostic criteria identified a low-risk group (composite event rate 0.8%/year, p 50%, HR 2.7, p=0.04; intermediate: LVEF 41-49%, HR 3.7, p=0.009; advanced: LVEF <40% HR 10.3, p<0.001). LGE was mostly subepicardial (87%). Circumferential (ring-like) LGE was more frequent in intermediate or advanced vs early disease (66% vs 48%, p<0.001). Conclusion This study identifies genotype-specific diagnostic and disease staging criteria for DSP cardiomyopathy that improve identification of risk for both heart failure and sustained ventricular arrhythmias. This work highlights how gene-specific criteria may be used to refine diagnosis and staging for cardiomyopathy subtypes – a critical step as gene-targeted treatments move toward clinical trials.

Year:

2025

BACKGROUND: Whether vigorous exercise increases risk of ventricular arrhythmias for individuals diagnosed and treated for congenital long QT syndrome (LQTS) remains unknown. METHODS: The National Institutes of Health–funded LIVE-LQTS study (Lifestyle and Exercise in the Long QT Syndrome) prospectively enrolled individuals 8 to 60 years of age with phenotypic and/or genotypic LQTS from 37 sites in 5 countries from May 2015 to February 2019. Participants (or parents) answered physical activity and clinical events surveys every 6 months for 3 years with follow-up completed in February 2022. Vigorous exercise was defined as ≥6 metabolic equivalents for >60 hours per year. A blinded Clinical Events Committee adjudicated the composite end point of sudden death, sudden cardiac arrest, ventricular arrhythmia treated by an implantable cardioverter defibrillator, and likely arrhythmic syncope. A National Death Index search ascertained vital status for those with incomplete follow-up. A noninferiority hypothesis (boundary of 1.5) between vigorous exercisers and others was tested with multivariable Cox regression analysis. RESULTS: Among the 1413 participants (13% <18 years of age, 35% 18–25 years of age, 67% female, 25% with implantable cardioverter defibrillators, 90% genotype positive, 49% with LQT1, 91% were treated with beta-blockers, left cardiac sympathetic denervation, and/or implantable cardioverter defibrillator), 52% participated in vigorous exercise (55% of these competitively). Thirty-seven individuals experienced the composite end point (including one sudden cardiac arrest and one sudden death in the nonvigorous group, one sudden cardiac arrest in the vigorous group) with overall event rates at 3 years of 2.6% in the vigorous and 2.7% in the nonvigorous exercise groups. The unadjusted hazard ratio for experience of events for the vigorous group compared with the nonvigorous group was 0.97 (90% CI, 0.57–1.67), with an adjusted hazard ratio of 1.17 (90% CI, 0.67–2.04). The upper 95% one-sided confidence level extended beyond the 1.5 boundary. Neither vigorous or nonvigorous exercise was found to be superior in any group or subgroup. CONCLUSIONS: Among individuals diagnosed with phenotypic and/or genotypic LQTS who were risk assessed and treated in experienced centers, LQTS-associated cardiac event rates were low and similar between those exercising vigorously and those not exercising vigorously. Consistent with the low event rate, CIs are wide, and noninferiority was not demonstrated. These data further inform shared decision-making discussions between patient and physician about exercise and competitive sports participation. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT02549664.

Year:

2024

Introduction Genetic testing is a cornerstone in the assessment of many cardiac diseases. However, variants are frequently classified as Variants of Unknown Significance (VUS), limiting the utility of testing. Recently, the DeepMind group (Google, USA) developed AlphaMissense, a unique Artificial Intelligence (AI) based model, based on language model principles for the prediction of missense variant pathogenicity. Objective To report on the performance of AlphaMissense, accessed by VarCardio, an open web-based variant annotation engine, in a real-world cardiovascular genetics center. Methods All genetic variants from an inherited arrhythmia program were examined using AlphaMissense via VarCard.io and compared to the ClinVar variant classification system, as well as another variant classification platform (Franklin by Genoox). The mutation reclassification rate and genotype phenotype concordance were examined for all variants in the study. Results We included 266 patients with heritable cardiac diseases, harboring 339 missense variants. Of those, 230 (67.8%) were classified by ClinVar as either VUS or non-classified. Using VarCard.io, 198 VUSs (86.1%, CI 80.9-90.3%) were reclassified to either Likely Pathgenic (LP) or Likely benign (LB). The reclassification rate was significantly higher for VarCard.io than for Franklin (86.1% vs 34.8%, p<0.001). Genotype-Phenotype concordance was highly aligned using VarCard.io predictions, at 95.9% (CI 92.8-97.9%) concordance rate. For 109 variants classified as Pathogenic, LP, Benign or LB by ClinVar, concordance with VarCard.io was high (90.5%). Conclusion AlphaMissense, accessed via VarCard.io, may be a highly efficient tool for cardiac genetic variant interpretation. The engine’s notable performance in assessing variants that are classified as VUS in ClinVar, demonstrates its potential to enhance cardiac genetic testing.

Year:

2024

BACKGROUND: Pathogenic variants in PKP2 (plakophilin-2) cause arrhythmogenic right ventricular cardiomyopathy, a disease characterized by life-threatening arrhythmias and progressive cardiomyopathy leading to heart failure. No effective medical therapy is available to prevent or arrest the disease. We tested the hypothesis that adeno-associated virus vector–mediated delivery of the human PKP2 gene to an adult mammalian heart deficient in PKP2 can arrest disease progression and significantly prolong survival. METHODS: Experiments were performed using a PKP2-cKO (cardiac-specific, tamoxifen-activated PKP2 knockout murine model). The potential therapeutic, adeno-associated virus vector of serotype rh.74 (AAVrh.74)-PKP2a (PKP2 variant A; RP-A601) is a recombinant AAVrh.74 gene therapy viral vector encoding the human PKP2 variant A. AAVrh.74-PKP2a was delivered to adult mice by a single tail vein injection either before or after tamoxifen-activated PKP2-cKO. PKP2 expression was confirmed by molecular and histopathologic analyses. Cardiac function and disease progression were monitored by survival analyses, echocardiography, and electrocardiography. RESULTS: Consistent with prior findings, loss of PKP2 expression caused 100% mortality within 50 days after tamoxifen injection. In contrast, AAVrh.74-PKP2a–mediated PKP2a expression resulted in 100% survival for >5 months (at study termination). Echocardiographic analysis revealed that AAVrh.74-PKP2a prevented right ventricle dilation, arrested left ventricle functional decline, and mitigated arrhythmia burden. Molecular and histological analyses showed AAVrh.74-PKP2a–mediated transgene mRNA and protein expression and appropriate PKP2 localization at the cardiomyocyte intercalated disc. Importantly, the therapeutic benefit was shown in mice receiving AAVrh.74-PKP2a after disease onset. CONCLUSIONS: These preclinical data demonstrate the potential for AAVrh.74-PKP2a (RP-A601) as a therapeutic for PKP2-related arrhythmogenic right ventricular cardiomyopathy in both early and more advanced stages of the disease.

Year:

2024

Collaborators (48)

Sharlene Day

Associate Professor

University of Pennsylvania

UNITED STATES
View details

Bryan Cannon

Professor of Pediatrics

Texas Children's Hospital

UNITED STATES
View details

Arthur A M Wilde

University of Amsterdam

NETHERLANDS
View details

Nisha Gilotra

Assistant Professor of Medicine

Johns Hopkins University School of Medicine

UNITED STATES
View details

Silvana Molossi

Associate Professor, Associate Chief of Cardiology

Baylor College of Medicine

UNITED STATES
View details

Firat Duru

-

SWITZERLAND
View details

Kristina Haugaa

Professor

University of Oslo

NORWAY
View details

A.s Amin

Cardiologist

Amsterdam University Medical Centers

NETHERLANDS
View details

Eric Smith

University of Michigan

UNITED STATES
View details

Julia Cadrin-Tourigny

Clinical Assistant Professor

Université de Montréal

CANADA
View details

J. Peter van Tintelen

Head Department; clinical geneticist

Universitair Medisch Centrum Utrecht

NETHERLANDS
View details

Gregory Webster

Northwestern University Feinberg School of Medicine

UNITED STATES
View details

Matthew Taylor

Professor

University of Colorado Anschutz Medical Campus

UNITED STATES
View details

Lia Crotti

Director of the Cardiological Rehabilitation Unit, San Luca Hospital

IRCCS Istituto Auxologico Italiano

ITALY
View details

Victoria N. Parikh

Stanford University

UNITED STATES
View details

Sing-Chien Yap

Researcher

Erasmus University Rotterdam

NETHERLANDS
View details

Michela Casella

Researcher

Università Politecnica delle Marche

ITALY
View details

Mario Delmar

Patricia M. and Robert H. Martinsen Professor of Cardiology and Professor of Cell Biology

NYU School of Medicine

UNITED STATES
View details

Belinda Gray

University of Sydney

AUSTRALIA
View details

Elijah R Behr

Director

University College London

UNITED KINGDOM
View details

Adam Helms

Assistant Professor

University of Michigan

UNITED STATES
View details

Maria Teresa Tome Esteban

Consultant cardiologist and Professor of Practice_ cardiology

St George’s, University of London

UNITED KINGDOM
View details

Petros Syrris

University College London

UNITED KINGDOM
View details

James Ware

Professor

Imperial College London

UNITED KINGDOM
View details

Marco Merlo

University of Trieste

ITALY
View details

Brian Olshansky

Electrophysiologist

-

UNITED STATES
View details

Gianfranco Sinagra

University of Trieste

ITALY
View details

Barbara Bauce

Associate Professor

University of Padova

ITALY
View details

Hugh Calkins

Johns Hopkins University School of Medicine

UNITED STATES
View details

Cynthia James

Associate Professor

Johns Hopkins University

UNITED STATES
View details

cristina basso

Professore Ordinario di Anatomia Patologica

University of Padova

ITALY
View details

Kalliopi Pilichou

Associate Professor

University of Padua

ITALY
View details

Ardan M. Saguner

-

SWITZERLAND
View details

Susan P Etheridge

-

UNITED STATES
View details

Katie Stiles

Assistant Professor of Research

Weill Cornell Medical College

UNITED STATES
View details

Wojciech Zareba

Professor of Medicine/Cardiology

University of Rochester Medical Center

UNITED STATES
View details

Anthony Aizer

Assistant Professor (Clinical) of Medicine (Academic)

NYU School of Medicine

UNITED STATES
View details

Luisa Mestroni

Professor of Medicine

University of Colorado Anschutz Medical Campus

UNITED STATES
View details

Juan Gimeno Blanes

Associate Professor

Universidad de Murcia

SPAIN
View details

Kimberly Harmon

Professor

University of Washington

UNITED STATES
View details

Marco Schiavone

Clinical Scientist

Centro Cardiologico Monzino

ITALY
View details

Prince Kannankeril

Professor

Vanderbilt University Medical Center

UNITED STATES
View details

Shubhayan Sanatani

Professor

The University of British Columbia

CANADA
View details

Rachel Lampert

Yale University School of Medicine

UNITED STATES
View details

David Park

Associate Professor of Medicine

NYU School of Medicine

UNITED STATES
View details

Giovanni Peretto

Vita-Salute San Raffaele University

ITALY
View details

Perry Elliott

University College London

UNITED KINGDOM
View details

Ilan Goldenberg

-

UNITED STATES
View details